Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Straumann Holding AG's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €1,947 Mil. Straumann Holding AG's Total Assets for the quarter that ended in Dec. 2023 was €3,522 Mil.
Therefore, Straumann Holding AG's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.55.
The historical rank and industry rank for Straumann Holding AG's Equity-to-Asset or its related term are showing as below:
FRA:QS51'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.47 Med: 0.57 Max: 0.64
Current: 0.55
During the past 13 years, the highest Equity to Asset Ratio of Straumann Holding AG was 0.64. The lowest was 0.47. And the median was 0.57.
FRA:QS51's Equity-to-Asset is ranked worse than 62.07% of 870
companies
in the Medical Devices & Instruments industry
Industry Median: 0.65
vs FRA:QS51: 0.55
Straumann Holding AG Equity-to-Asset Historical Data
The historical data trend for Straumann Holding AG's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Straumann Holding AG's Equity-to-Asset
For the Medical Instruments & Supplies subindustry, Straumann Holding AG's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Straumann Holding AG's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Straumann Holding AG's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Straumann Holding AG's Equity-to-Asset falls into.
Straumann Holding AG Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Straumann Holding AG's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Straumann Holding AG (FRA:QS51) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Straumann Holding AG Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Straumann Holding AG's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Straumann Holding AG (FRA:QS51) Business Description
Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The company's core products are dental implants, and it holds roughly 30% of the global implant dentistry market, which is estimated to be worth roughly CHF 5.4 billion. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:QS51 has been successfully added to your 